

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



STARCOIN GROUP LIMITED

星太鏈集團有限公司

(Formerly known as Innovative Pharmaceutical Biotech Limited 領航醫藥及生物科技有限公司)

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

VOLUNTARY ANNOUNCEMENT

MEMORANDUM OF UNDERSTANDING

This announcement is made by Starcoin Group Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce that on 13 October 2025 (after trading hours of the Stock Exchange), the Company entered into the memorandum of understanding (the “**MOU**”) with Starcoin Foundation indicating the intention of Starcoin Foundation to issue Starcoin Tokens (the “**Token Issue**”) on the basis of one Starcoin Token for every ten existing shares of the Company (the “**Shares**”) held on the date for determination of entitlements to the issue of Starcoin Tokens to be determined by the Company (the “**Record Date**”) by the shareholders of the Company (the “**Shareholders**”).

Save for the terms in relation to confidentiality, costs and governing laws contained in the MOU, the MOU is not legally binding or enforceable.

INFORMATION OF STARCOIN FOUNDATION

Starcoin Foundation is a non-profit organization established under the laws of Republic of Panama and is founded by Dr. Yeung Yung, the president of Starcoin Foundation and the chairman and executive director of the Company. It is principally engaged in smart-contract key management, DAO governance/treasury access, and token custody for project development and operations.

REASONS AND BENEFITS FOR THE TOKEN ISSUE

The Company is an investment holding company and its subsidiaries are principally engaged in the trading of beauty equipment and products in Hong Kong and research, development and commercialisation of the oral insulin product.

The Token Issue represents the first “token-stock linkage” project directly initiated and endorsed by a publicly traded company in Asia. This initiative is the Company’s foundational platform for the global Web3 digital capital market, with each Starcoin Token backed by U.S. dollar assets. The goal of the Token Issue is to build an integrated on-chain investment banking system focused on the on-chain issuance, compliance and global circulation of Real World Assets (RWA).

The Group plans to leverage the advantages of blockchain technology to reshape traditional financial business processes. By creating a Web3 investment bank, the Group aims to become the key link between global assets and digital investors. The Token Issue will be deployed on the Conflux eSpace public blockchain.

Taking into account of the above, the Board (including the independent non-executive Directors) considers that the terms of the MOU are fair and reasonable and are entered into on normal commercial terms and in the interests of the Group and its shareholders as a whole.

Further announcement(s) will be made by the Company in compliance with the Listing Rules as and when appropriate and if there is any material development in this matter.

GENERAL

The Token Issue is subject to the further negotiations between the Company and Starcoin Foundation and the Token Issue therefore may or may not proceed. The Company will publish an announcement in compliance with the Listing Rules as when and appropriate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Starcoin Group Limited
Yeung Yung
Chairman

Hong Kong, 13 October 2025

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkan, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: starcoingroup.com.